Literature DB >> 23959592

Mental health affects the quality of life and recovery after liver transplantation.

Lisa Renee Miller1, Daniel Paulson, Anne Eshelman, Mary Bugenski, Kimberly A Brown, Dilip Moonka, Marwan Abouljoud.   

Abstract

There has been little research examining the effects of mental health before liver transplantation on quality of life (QOL) and recovery after transplantation. Therefore, the purpose of the current study was to examine how pretransplant depression and anxiety affect mental health, QOL, and recovery after transplantation. Eighty-two transplant recipients provided data when they were listed for transplantation and 6 months after transplantation. Pretransplant anxiety predicted posttransplant anxiety (P < 0.001), and there was a trend in predicting posttransplant depression (P = 0.06). Pretransplant depression predicted posttransplant depression (P = 0.03), and there was a trend in predicting posttransplant anxiety (P = 0.06). Additionally, pretransplant anxiety predicted posttransplant QOL for several domains, including Body Pain, Role Limitations Due to Emotional Problems, and Mental Health, as well as the Mental Health Composite Score (P < 0.05). However, in comparison with anxiety, pretransplant depression independently predicted outcomes for more QOL domains, which included Physical Functioning, Role Limitations Due to Physical Problems, General Health, Vitality, and Social Functioning, as well as the Physical Composite Score (P < 0.05). Patients with depression at the baseline were more likely to report incomplete recovery 6 months after transplantation (P < 0.001). With respect to baseline anxiety, there was a trend suggesting that these patients were also more likely to report incomplete recovery (P = 0.09). These findings highlight the importance of evaluating transplant candidates both before and after transplantation for anxiety and depressive symptoms. Once patients with these symptoms are identified, they can be referred for treatment, which may lead to better posttransplant outcomes for mental health, QOL, and recovery.
© 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2013        PMID: 23959592     DOI: 10.1002/lt.23728

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  6 in total

1.  Health-related quality of life and affective status in liver transplant recipients and patients on the waiting list with low MELD scores.

Authors:  Christian Benzing; Nicco Krezdorn; Julia Förster; Andreas Hinz; Felix Krenzien; Georgi Atanasov; Moritz Schmelzle; Hans-Michael Hau; Michael Bartels
Journal:  HPB (Oxford)       Date:  2016-04-20       Impact factor: 3.647

Review 2.  Assessment of mental health in patients with chronic liver disease.

Authors:  Maureen P Whitsett; Arpita Goswami Banerjee; Marina Serper
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-07-16

3.  The feasibility of a group stress management Liver SMART intervention for patients with end-stage liver disease: A pilot study.

Authors:  Devika R Jutagir; Rebecca M Saracino; Amy Cunningham; Kelly A Foran-Tuller; Mary A Driscoll; William H Sledge; Sukru H Emre; Dwain C Fehon
Journal:  Palliat Support Care       Date:  2018-06-04

4.  Factors associated with acute and chronic pain after inguinal herniorraphy.

Authors:  Elif Erdogan; Ecder Ozenc
Journal:  Rom J Anaesth Intensive Care       Date:  2018-04

5.  Liver Transplantation for Quality as well as Quantity of Life.

Authors:  Kamran B Lankarani
Journal:  Hepat Mon       Date:  2013-10-01       Impact factor: 0.660

6.  Pre-Transplant Depression Is Associated with Length of Hospitalization, Discharge Disposition, and Survival after Liver Transplantation.

Authors:  Shari S Rogal; Gautham Mankaney; Viyan Udawatta; Matthew Chinman; Chester B Good; Susan Zickmund; Klaus Bielefeldt; Alexis Chidi; Naudia Jonassaint; Alison Jazwinski; Obaid Shaikh; Christopher Hughes; Paulo Fontes; Abhinav Humar; Andrea DiMartini
Journal:  PLoS One       Date:  2016-11-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.